Dasatinib
C-KIT Mutation
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the C-KIT Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Azacitidine Children's Hospital of Soochow University | Phase 2 | CCC |
Avapritinib Children's Hospital of Soochow University | Phase 2 | CCC |
Decitabine Children's Hospital of Soochow University | Phase 2 | CCC |
Cytosin-Arabinosid Children's Hospital of Soochow University | Phase 2 | CCC |
Idarubicine Children's Hospital of Soochow University | Phase 2 | CCC |
FILGRASTIM Children's Hospital of Soochow University | Phase 2 | CCC |
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →